Mecasermin 40mg/4ml solution for injection vials
Requires a prescription from a doctor or prescriber
Mecasermin contains recombinant-DNA-engineered human insulin-like growth factor-1 (rhIGF-1)[FDA Label].
Safety information for pregnancy and breastfeeding
Pregnancy
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Mecasermin
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Mecasermin
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Mecasermin on the MHRA register
Increlex 40mg/4ml solution for injection vials
WHO defined daily dose (DDD)
2 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 9 · 1995–2026
Showing the 50 most relevant studies, sorted by most relevant.
Fernanda Cristina Poscai Ribeiro, Maria Luiza Alves, Alice Campos Meneses, et al.
Neurogenetics, 2025
- Insulin-Like Growth Factor I
- Rett Syndrome
- Mutation
Omar Khwaja, Eugenia Ho, Katherine V. Barnes, et al.
Proceedings of the National Academy of Sciences, 2014
- Insulin-Like Growth Factor I
- Recombinant Proteins
- Rett Syndrome
Arlan L. Rosenbloom
Advances in Therapy, 2009
- Cardiovascular Diseases
- Central Nervous System Diseases
- Clinical Trials as Topic
Michaela Plamper, Bettina Gohlke, Felix Schreiner, et al.
International Journal of Molecular Sciences, 2018
- Blood Glucose
- Insulin
- Insulin Resistance
Heather M. O’Leary, Walter E. Kaufmann, Katherine V. Barnes, et al.
Annals of Clinical and Translational Neurology, 2018
Rachel M. Williams, Anna McDonald, Martin O'Savage, et al.
Expert Opinion on Drug Metabolism & Toxicology, 2008
- Bone Diseases, Metabolic
- Burns
- Diabetes Mellitus
S Chernausek, P Backeljauw, J Frane, et al.
Australian Prescriber, 2022
Gillian M. Keating
BioDrugs, 2008
- Anorexia Nervosa
- Clinical Trials as Topic
- Diabetes Mellitus, Type 1
G. Pini, L. Congiu, A. Benincasa, et al.
Autism Research and Treatment, 2016
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
5.8 hours
Mechanism
Mecasermin supplies recombinant-DNA-origin IGF-1, which binds to the Type I IGF-1 receptor.
Food interactions
1 warning
Human targets
5 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
100%
Half-life
5.8 hours
Protein binding
80%
Volume of distribution
0.073 L/kg
Metabolism
[A176017]…
Elimination
[A176017]…
Clearance
0.04L/h
* Clearance is estimated to be 0.04L/hr/kg…
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
[A2322]
It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 605 interactions
The effects of Mecasermin in human pregnancy has not been studied, however effects on fetal development in animal studies were only seen at doses higher than the maximum recommended human dose based on body surface area.
Studies on excretion of the drug in human milk, use in patients under 2 years, use in patients over 65 years, or use in patients with renal or hepatic impairment have not been performed.
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A176017]
[A176017]
* Clearance is estimated to be 0.04L/hr/kg at 0.5 micrograms/mL of IGFBP-3
* Clearance is estimated to be 0.01L/hr/kg at 3 micrograms/mL of IGFBP-3 (the median level of IGFBP-3 for patients with normal IGF-1 levels)
Proteins and enzymes this drug interacts with in the body
May play a role in synapse maturation .
PMID:21076856 PMID:24132240
Ca(2+)-dependent exocytosis of IGF1 is required for sensory perception of smell in the olfactory bulb (By similarity). Acts as a ligand for IGF1R. Binds to the alpha subunit of IGF1R, leading to the activation of the intrinsic tyrosine kinase activity which autophosphorylates tyrosine residues in the beta subunit thus initiating a cascade of down-stream signaling events leading to activation of the PI3K-AKT/PKB and the Ras-MAPK pathways.
Binds to integrins ITGAV:ITGB3 and ITGA6:ITGB4. Its binding to integrins and subsequent ternary complex formation with integrins and IGFR1 are essential for IGF1 signaling. Induces the phosphorylation and activation of IGFR1, MAPK3/ERK1, MAPK1/ERK2 and AKT1 .
PMID:19578119 PMID:22351760 PMID:23243309 PMID:23696648
As part of the MAPK/ERK signaling pathway, acts as a negative regulator of apoptosis in cardiomyocytes via promotion of STUB1/CHIP-mediated ubiquitination and degradation of ICER-type isoforms of CREM (By similarity)
IGF1R is crucial for tumor transformation and survival of malignant cell. Ligand binding activates the receptor kinase, leading to receptor autophosphorylation, and tyrosines phosphorylation of multiple substrates, that function as signaling adapter proteins including, the insulin-receptor substrates (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway and the Ras-MAPK pathway.
The result of activating the MAPK pathway is increased cellular proliferation, whereas activating the PI3K pathway inhibits apoptosis and stimulates protein synthesis. Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K (PIK3R1), leading to activation of several downstream substrates, including protein AKT/PKB. AKT phosphorylation, in turn, enhances protein synthesis through mTOR activation and triggers the antiapoptotic effects of IGFIR through phosphorylation and inactivation of BAD.
In parallel to PI3K-driven signaling, recruitment of Grb2/SOS by phosphorylated IRS1 or Shc leads to recruitment of Ras and activation of the ras-MAPK pathway. In addition to these two main signaling pathways IGF1R signals also through the Janus kinase/signal transducer and activator of transcription pathway (JAK/STAT). Phosphorylation of JAK proteins can lead to phosphorylation/activation of signal transducers and activators of transcription (STAT) proteins.
In particular activation of STAT3, may be essential for the transforming activity of IGF1R. The JAK/STAT pathway activates gene transcription and may be responsible for the transforming activity. JNK kinases can also be activated by the IGF1R.
IGF1 exerts inhibiting activities on JNK activation via phosphorylation and inhibition of MAP3K5/ASK1, which is able to directly associate with the IGF1R
PMID:10874028 PMID:19556345
Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R .
PMID:20353938
Inhibits the positive effect of humanin on insulin sensitivity .
PMID:19623253
Promotes testicular germ cell apoptosis .
PMID:19952275
Acts via LRP-1/alpha2M receptor, also known as TGF-beta type V receptor, to mediate cell growth inhibition independent of IGF1 .
PMID:9252371
Mechanistically, induces serine-specific dephosphorylation of IRS1 or IRS2 upon ligation to its receptor, leading to the inhibitory cascade .
PMID:15371331
In the nucleus, interacts with transcription factors such as retinoid X receptor-alpha/RXRA to regulate transcriptional signaling and apoptosis PMID:10874028
Phosphorylation of IRSs proteins lead to the activation of two main signaling pathways: the PI3K-AKT/PKB pathway, which is responsible for most of the metabolic actions of insulin, and the Ras-MAPK pathway, which regulates expression of some genes and cooperates with the PI3K pathway to control cell growth and differentiation. Binding of the SH2 domains of PI3K to phosphotyrosines on IRS1 leads to the activation of PI3K and the generation of phosphatidylinositol-(3, 4, 5)-triphosphate (PIP3), a lipid second messenger, which activates several PIP3-dependent serine/threonine kinases, such as PDPK1 and subsequently AKT/PKB. The net effect of this pathway is to produce a translocation of the glucose transporter SLC2A4/GLUT4 from cytoplasmic vesicles to the cell membrane to facilitate glucose transport.
Moreover, upon insulin stimulation, activated AKT/PKB is responsible for: anti-apoptotic effect of insulin by inducing phosphorylation of BAD; regulates the expression of gluconeogenic and lipogenic enzymes by controlling the activity of the winged helix or forkhead (FOX) class of transcription factors. Another pathway regulated by PI3K-AKT/PKB activation is mTORC1 signaling pathway which regulates cell growth and metabolism and integrates signals from insulin. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 thereby activating mTORC1 pathway.
The Ras/RAF/MAP2K/MAPK pathway is mainly involved in mediating cell growth, survival and cellular differentiation of insulin. Phosphorylated IRS1 recruits GRB2/SOS complex, which triggers the activation of the Ras/RAF/MAP2K/MAPK pathway. In addition to binding insulin, the insulin receptor can bind insulin-like growth factors (IGFI and IGFII).
Isoform Short has a higher affinity for IGFII binding. When present in a hybrid receptor with IGF1R, binds IGF1. PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR isoform Long are activated with a high affinity by IGF1, with low affinity by IGF2 and not significantly activated by insulin, and that hybrid receptors composed of IGF1R and INSR isoform Short are activated by IGF1, IGF2 and insulin.
In contrast, PubMed:16831875 shows that hybrid receptors composed of IGF1R and INSR isoform Long and hybrid receptors composed of IGF1R and INSR isoform Short have similar binding characteristics, both bind IGF1 and have a low affinity for insulin. In adipocytes, inhibits lipolysis (By similarity)
PMID:18817523 PMID:2963003
Lysosomal enzymes bearing phosphomannosyl residues bind specifically to mannose-6-phosphate receptors in the Golgi apparatus and the resulting receptor-ligand complex is transported to an acidic prelysosomal compartment where the low pH mediates the dissociation of the complex .
PMID:18817523 PMID:2963003
The receptor is then recycled back to the Golgi for another round of trafficking through its binding to the retromer .
PMID:18817523
This receptor also binds IGF2 .
PMID:18046459
Acts as a positive regulator of T-cell coactivation by binding DPP4 PMID:10900005
Proteins that carry this drug through the body
PMID:10874028 PMID:19556345
Also exhibits IGF-independent antiproliferative and apoptotic effects mediated by its receptor TMEM219/IGFBP-3R .
PMID:20353938
Inhibits the positive effect of humanin on insulin sensitivity .
PMID:19623253
Promotes testicular germ cell apoptosis .
PMID:19952275
Acts via LRP-1/alpha2M receptor, also known as TGF-beta type V receptor, to mediate cell growth inhibition independent of IGF1 .
PMID:9252371
Mechanistically, induces serine-specific dephosphorylation of IRS1 or IRS2 upon ligation to its receptor, leading to the inhibitory cascade .
PMID:15371331
In the nucleus, interacts with transcription factors such as retinoid X receptor-alpha/RXRA to regulate transcriptional signaling and apoptosis PMID:10874028
PMID:11397844 PMID:15972819
Also plays a positive role in cell migration by interacting with integrin ITGA5:ITGB1 through its RGD motif .
PMID:7504269
Mechanistically, binding to integrins leads to activation of focal adhesion kinase/PTK2 and stimulation of the mitogen-activated protein kinase (MAPK) pathway .
PMID:11397844
Regulates cardiomyocyte apoptosis by suppressing HIF-1alpha/HIF1A ubiquitination and subsequent degradation (By similarity)
PMID:18563800 PMID:38796567
Functions coordinately with receptor protein tyrosine phosphatase beta/PTPRB and the IGF1 receptor to regulate IGF1-mediated signaling by stimulating the phosphorylation of PTEN leading to its inactivation and AKT1 activation .
PMID:22869525
Plays a positive role in cell migration via interaction with integrin alpha5/ITGA5 through an RGD motif .
PMID:16569642
Additionally, interaction with ITGA5/ITGB1 enhances the adhesion of endothelial progenitor cells to endothelial cells .
PMID:26076738
Upon mitochondrial damage, facilitates apoptosis with ITGA5 of podocytes, and then activates the phosphorylation of focal adhesion kinase (FAK)-mediated mitochondrial injury PMID:38796567
PMID:18930415 PMID:7683690
Increases the cell proliferation of osteoblasts, intestinal smooth muscle cells and neuroblastoma cells. Enhances adhesion and survival of epithelial cells but decreases adhesion of mesenchymal cells (By similarity). Once secreted, acts as a major mediator of mTORC1-dependent feedback inhibition of IGF1 signaling (By similarity).
Also plays a role in the induction of extracellular matrix (ECM) production and deposition independently of its nuclear translocation and binding to IGFs .
PMID:20345844 PMID:26103640
Acts itself as a growth factor that can act independently of IGFs to regulate bone formation. Acts as a ligand for the ROR1 receptor which triggers formation of ROR1/HER2 heterodimer to enhance CREB oncogenic signaling PMID:36949068
ATC H01AC03
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Mecasermin
Additional database identifiers
Drugs Product Database (DPD)
23544
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5464
GenAtlas
IGF1
GeneCards
IGF1
GenBank Gene Database
M14155
UniProt Accession
IGF1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5465
GenAtlas
IGF1R
GeneCards
IGF1R
GenBank Gene Database
X04434
GenBank Protein Database
804990
Guide to Pharmacology
1801
UniProt Accession
IGF1R_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5472
GenAtlas
IGFBP3
GeneCards
IGFBP3
GenBank Gene Database
M31159
GenBank Protein Database
183116
UniProt Accession
IBP3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:6091
GenAtlas
INSR
GeneCards
INSR
GenBank Gene Database
M10051
GenBank Protein Database
307070
Guide to Pharmacology
1800
UniProt Accession
INSR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5467
GeneCards
IGF2R
GenBank Gene Database
Y00285
GenBank Protein Database
33055
UniProt Accession
MPRI_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5472
GenAtlas
IGFBP3
GeneCards
IGFBP3
GenBank Gene Database
M31159
GenBank Protein Database
183116
UniProt Accession
IBP3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5468
GeneCards
IGFALS
UniProt Accession
ALS_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5469
GeneCards
IGFBP1
UniProt Accession
IBP1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5471
GeneCards
IGFBP2
UniProt Accession
IBP2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5473
GeneCards
IGFBP4
UniProt Accession
IBP4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5474
GeneCards
IGFBP5
UniProt Accession
IBP5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:5475
GeneCards
IGFBP6
UniProt Accession
IBP6_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q6804390), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.